



# Pharmaids Pharmaceuticals Limited

Date: 13.08.2020

To

Department of Corporate Service  
BSE Limited  
PJ Towers, Dalal Street,  
Fort Mumbai-400001.  
Dear Sir / Madam,

**BSE Script Code: 524572**

**Subject: Outcome of Board Meeting – August 13, 2020**

The Board of Directors of the Company at their meeting held today i.e. Thursday, August 13, 2020 has inter alia, considered and approved the following business:

- 1) Approval of unaudited Financial Results for the Quarter ended 30<sup>th</sup> June,2020  
Pursuant to regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, The Board of Directors have approved the unaudited Financial Results of the company for the Quarter ended June 30, 2020, which are enclosed herewith along with the Limited Review Reports issued by M/s. PPKG & Co, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at [www.pharmaids.com](http://www.pharmaids.com) and also on the website of BSE Ltd. Viz. [www.bseindia.com](http://www.bseindia.com).
- 2) To consider and approve the draft Notice, Directors Report along with other related documents for the forthcoming AGM.  
Approved the notice of 31<sup>st</sup> Annual General Meeting of the company to be held on Thursday, September 17, 2020 through Video Conference or Other Audio-Visual Means as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India vide dt 05.05.2020 and 12.05.2020, respectively
- 3) In accordance with SEBI [LODR) Regulations, 2015 and Companies Act, 2013, the Company is providing the facility for e-voting through electronic means, as an alternate, to all its members to enable them to cast their votes electronically. The following are the details of the same:

Sr. No.	Particulars	Details
1.	E-voting start Date	September 14, 2020- 9.00A.M
2.	E-voting end Date	September 16, 2020- 5.00P.M
3.	Cut-off date for e-voting	September 09, 2020

The e-voting facility is being provided through CDSL'S e-voting platform and can be accessed by clicking on/ viewing the link <http://www.evotingindia.com>. All the instructions are given in the notice of AGM for voting through the e-voting platform. The Company has appointed Mr. Kashinath Sahu, Practicing Company Secretary as Scrutinizer for conducting the e-voting process for the 31<sup>st</sup> AGM in a fair and transparent manner.


The meeting of the Board of Directors of the Company Commenced at 3.00 PM and concluded at 4.45 pm.


Please take note of the same on your record.

Thanking You,

Yours faithfully

For **Pharmaids Pharmaceuticals Limited**

  
S. Padmaja Kalyani  
Director (DIN: 03096445)



Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : [pharmaids125@gmail.com](mailto:pharmaids125@gmail.com) , Web : [www.pharmaids.com](http://www.pharmaids.com)



# Pharmaids Pharmaceuticals Limited


Statement of Profit and Loss for the Quarter ended 30 June 2020				
Particulars	(Rs in Lakhs)			
	Quarter ended			Year ended
	30/06/2020	31/03/2020	30/06/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Audited
Income				
Revenue from Operations	-	-	1.20	-
Other Income	2.63	-	-	-
<b>Total Income</b>	<b>2.63</b>	<b>-</b>	<b>1.20</b>	<b>-</b>
Expenses				
Cost of Material Consumed	-	-	-	-
Purchase of Stock in Trade	-	-	-	-
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-
Employee benefit expenses	0.30	0.46	0.96	2.28
Finance Cost	-	-	0.09	0.08
Depreciation and amortisation expense	1.11	1.09	0.71	3.88
Other expenses	0.88	2.05	6.25	31.27
<b>Total expenses</b>	<b>2.29</b>	<b>3.60</b>	<b>8.01</b>	<b>37.52</b>
Profit/ (loss) before exceptional items and tax	0.34	(3.60)	(6.81)	(37.52)
Exceptional items	-	-	-	-
<b>Profit/ (loss) before tax</b>	<b>0.34</b>	<b>(3.60)</b>	<b>(6.81)</b>	<b>(37.52)</b>
Tax expenses:				
(1) Current Tax	-	-	-	-
(2) Deferred Tax	-	(40.87)	-	(40.87)
Profit/ (loss) for the period from continuing operations	0.34	37.27	(6.81)	3.35
Profit/ (loss) from discontinued operations	-	-	-	-
Tax expense of discontinued operations	-	-	-	-
Profit/ (loss) from discounting operations (after tax)	-	-	-	-
<b>Profit/ (loss) for the period</b>	<b>0.34</b>	<b>37.27</b>	<b>(6.81)</b>	<b>3.35</b>
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	-	-	-	-
(Profit/ loss + other comprehensive income)	-	-	-	-
<b>Earnings per equity share (for continuing operations)</b>				
a) Basic	0.00	0.36	(0.07)	0.03
b) Diluted	0.00	0.36	(0.07)	0.03
<b>Earnings per equity share (for discontinued operations)</b>				
a) Basic	-	-	-	-
b) Diluted	-	-	-	-
<b>Earnings per equity share (for discontinued &amp; continuing operations)</b>				
a) Basic	0.00	0.36	(0.07)	0.03
b) Diluted	0.00	0.36	(0.07)	0.03

NOTES: (1). The above results were approved at the meeting of the Board of Directors held on August 13, 2020. (2). The Company operates in a single segment (3). As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. (4). As per NCLT order dated 27-09-2019, Pharmaids Pharmaceuticals Limited undergone amalgamation with Emergent Bio Naturals Limited w.e.f 01-04-2018 as explained in Para 5 of the Auditor's Report. (5). The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period. (6). During this pandemic, business operations and financial position has revealed that there has been no significant impact on company's financial results as at 30th June 2020. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor such impact to future economic conditions.

Place: Hyderabad  
Date: 13/08/2020

For Pharmaids Pharmaceuticals Limited

S. Padmaja Kalyani  
Director (DIN: 03096445)



Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151  
CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW  
Email : pharmaids125@gmail.com , Web : www.pharmaids.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM FINANCIAL RESULTS**

To

The Board of Directors,  
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited Financial Results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the Quarter Ended 30<sup>th</sup> June, 2020 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Scheme of Amalgamation of Emergent Bio Naturals Limited (EBNL) with Pharmaids Pharmaceuticals Limited was approved by the National Company Law Tribunal vide its order dated 27th September, 2019. The certified copy of the NCLT order was filed with Registered of Companies on 12th October, 2019 consequently the Scheme became operative, and effective date is 1st April, 2018 (Appointed Date). The Company has accounted the Amalgamation as per Appendix C of IND AS 103 Business Combination, the financial information in respect of prior periods has been restated as if the business combination had occurred on April 1st, 2018.



Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Previously issued financial information of the Company for the quarter ended 30<sup>th</sup> June, 2019 included in the Statement, have been restated to give effect to the Scheme of Amalgamation ("the Scheme") of Pharmaids Pharmaceuticals Limited (PPL) with Emergent Bio Naturals Limited, as explained in Para 5 to the Report.

The adjustments made to the previously issued financial information to give effect to the Scheme have been reviewed by us. Our report is not modified in respect of this matter.

Place : Hyderabad  
Date : 13<sup>th</sup> August, 2020

For PPKG & CO  
Chartered Accountants  
FRN No. 009655S

GIRDHARI LAL TOSHWIHAL  
(Partner)  
M. No. 205140

UDIN: 20205140AAAABTS328



# Pharmaids Pharmaceuticals Limited

13<sup>th</sup> August, 2020

To  
The General Manager  
Corporate Relations Department  
BSE Limited  
P.J. Towers, Dalal Street, Mumbai-400001

Dear Sir,

**Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.**

**Ref No. Scrip Code: 524572**

## **DECLARATION FOR UNMODIFIED OPINION**

I, S. Padmaja Kalyani, Director of M/ s. Pharmaids Pharmaceuticals Limited having its Registered office at 4-4-211/212/3, 1<sup>st</sup> Floor Inderbagh, Sultan Bazar, Hyderabad-500095, Telangana and having its Corporate Office at 503, Amrutha Estate, Himayath Nagar, Hyderabad-500029, hereby declare that, M/s. PPKG & Co, Statutory Auditors of the Company, have issued a Limited Review Report with Unmodified Opinion on Financial Results for the Quarter Ended 30<sup>th</sup> June, 2020.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015 as amended vide its circular no CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Thanking You,

Yours Faithfully,

For **Pharmaids Pharmaceuticals Limited**

*Padmaf.*  
S. Padmaja Kalyani  
Director

